BioGeneration Ventures closes $167M fund to hatch European startups with backing from Eli Lilly, Novo, BMS
BioGeneration Ventures, a Dutch venture capital firm dedicated to early-stage biotech startups, has closed its fifth fund at €150 million ($167 million).
While BGV, based in Naarden, Netherlands, is focused on drug developers out of Europe, the fund attracted a number of financial institutions or life sciences companies of US origin, which make up 78% of the new investor base. Its existing corporate investors, Eli Lilly, Novo Holdings and Bristol Myers Squibb, also returned for Fund V.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.